Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
Authors
Keywords
-
Journal
World Journal of Gastrointestinal Oncology
Volume 10, Issue 5, Pages 108-114
Publisher
Baishideng Publishing Group Inc.
Online
2018-05-15
DOI
10.4251/wjgo.v10.i5.108
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost.
- (2017) David Edward Kaplan et al. JOURNAL OF CLINICAL ONCOLOGY
- The effect of sorafenib (S) starting dose and dose intensity on survival in patients with advanced hepatocellular carcinoma (HCC).
- (2017) Mohammed Abdullah Alghamdi et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
- (2016) Kenji Ikeda et al. JOURNAL OF GASTROENTEROLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments
- (2013) I-Cheng Lee et al. INTERNATIONAL JOURNAL OF CANCER
- Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy
- (2013) Wen-jun Ma et al. World Journal of Surgical Oncology
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2012) Bassam Estfan et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma
- (2012) Dominik Bettinger et al. HEPATOLOGY
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
- (2012) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis
- (2009) M. Pinter et al. ONCOLOGIST
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started